{"symbol": "LLY", "publishedDate": "2021-01-15 06:45:00", "publisher": "PRNewsWire", "title": "Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund", "image": "https://images.financialmodelingprep.com/news/lilly-announces-30-million-limited-partner-investment-in-unseen-20210115.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP, a newly-formed venture fund created by racially diverse and historically underrepresented business leaders that is...", "url": "https://www.prnewswire.com/news-releases/lilly-announces-30-million-limited-partner-investment-in-unseen-capital-health-fund-301209062.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-15T06:45:00-05:00", "date_et": "2021-01-15"}
{"symbol": "LLY", "publishedDate": "2021-01-15 17:02:00", "publisher": "PRNewsWire", "title": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement", "image": "https://images.financialmodelingprep.com/news/lilly-confirms-date-and-conference-call-for-fourthquarter-2020-20210115.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the investment community and media to further detail...", "url": "https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-fourth-quarter-2020-financial-results-announcement-301209566.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-15T17:02:00-05:00", "date_et": "2021-01-15"}
{"symbol": "LLY", "publishedDate": "2021-01-18 13:52:03", "publisher": "Seeking Alpha", "title": "Dividend Growth Pharmaceuticals For 2021", "image": "https://images.financialmodelingprep.com/news/dividend-growth-pharmaceuticals-for-2021-20210118.jpg", "site": "seekingalpha.com", "text": "Merck and Amgen are major pharmaceuticals that experienced slowing sales in the mid 2010s due to patent expirations and biosimilar competition. However, Merck recently experienced strong bottom line growth due to their expanding oncology and vaccine divisions.", "url": "https://seekingalpha.com/article/4399528-dividend-growth-pharmaceuticals-for-2021", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-18T13:52:03-05:00", "date_et": "2021-01-18"}
{"symbol": "LLY", "publishedDate": "2021-01-19 06:30:00", "publisher": "PRNewsWire", "title": "Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies", "image": "https://images.financialmodelingprep.com/news/lilly-and-merus-nv-announce-collaboration-to-discover-novel-20210119.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a...", "url": "https://www.prnewswire.com/news-releases/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies-301210513.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-19T06:30:00-05:00", "date_et": "2021-01-19"}
{"symbol": "LLY", "publishedDate": "2021-01-19 08:05:00", "publisher": "Barron's", "title": "Eli Lilly Stock Is Still Pricey. Why It Might Be a Buy.", "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-is-still-pricey-why-it-might-20210119.jpg", "site": "barrons.com", "text": "After its Alzheimer's trial success, an analyst at Miuzho upgraded Eli Lilly shares from Hold to Buy.", "url": "https://www.barrons.com/articles/eli-lilly-stock-is-still-pricey-why-it-might-be-a-buy-51611061529", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-19T08:05:00-05:00", "date_et": "2021-01-19"}
{"symbol": "LLY", "publishedDate": "2021-01-19 09:05:12", "publisher": "Seeking Alpha", "title": "Invest Like A Billionaire With High Yield: THW", "image": "https://images.financialmodelingprep.com/news/invest-like-a-billionaire-with-high-yield-thw-20210119.jpg", "site": "seekingalpha.com", "text": "Invest Like A Billionaire With High Yield: THW", "url": "https://seekingalpha.com/article/4399114-invest-like-billionaire-high-yield-thw", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-19T09:05:12-05:00", "date_et": "2021-01-19"}
{"symbol": "LLY", "publishedDate": "2021-01-19 14:42:32", "publisher": "Benzinga", "title": "Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade", "image": "https://images.financialmodelingprep.com/news/lilly-awash-in-catalysts-pipeline-updates-mizuho-says-in-upgrade-20210119.jpg", "site": "benzinga.com", "text": "Eli Lilly And Co (NYSE: LLY) received an upgrade from a Mizuho Securities analyst ahead of a key data readout in March. The Lilly Analyst: Vamil Divan upgraded Lilly shares from Neutral to Buy and increased the price target from $164 to $222.", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/21/01/19217446/lilly-awash-in-catalysts-pipeline-updates-mizuho-says-in-upgrade", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-19T14:42:32-05:00", "date_et": "2021-01-19"}
{"symbol": "LLY", "publishedDate": "2021-01-20 06:47:04", "publisher": "Zacks Investment Research", "title": "Lilly (LLY) Inks Deal With Merus to Discover Cancer Antibodies", "image": "https://images.financialmodelingprep.com/news/lilly-lly-inks-deal-with-merus-to-discover-cancer-20210120.jpg", "site": "zacks.com", "text": "Eli Lilly (LLY) signs a deal with Merus to develop novel T-cell re-directing bispecific antibodies. While Merus will lead early-stage development, Loxo Oncology will take care of further development and commercialization.", "url": "https://www.zacks.com/stock/news/1248924/lilly-lly-inks-deal-with-merus-to-discover-cancer-antibodies", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-20T06:47:04-05:00", "date_et": "2021-01-20"}
{"symbol": "LLY", "publishedDate": "2021-01-20 07:35:09", "publisher": "Market Watch", "title": "Lilly signs cancer drug deal worth up to $1.6 billion", "image": "https://images.financialmodelingprep.com/news/lilly-signs-cancer-drug-deal-worth-up-to-16-20210120.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. gained 0.8% in premarket trading on Wednesday, the day after the drugmaker announced a deal worth up to $1.6 billion with Merus to develop three antibody therapies aimed at treating cancer. The Dutch company's stock was down 5.1% in premarket trading on Wednesday.", "url": "https://www.marketwatch.com/story/lilly-signs-cancer-drug-deal-worth-up-to-16-billion-2021-01-20", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-20T07:35:09-05:00", "date_et": "2021-01-20"}
{"symbol": "LLY", "publishedDate": "2021-01-21 06:15:00", "publisher": "The Motley Fool", "title": "3 Top Stocks for Retirees", "image": "https://images.financialmodelingprep.com/news/3-top-stocks-for-retirees-20210121.jpg", "site": "fool.com", "text": "Investors can buy and hold these stocks without losing sleep at night.", "url": "https://www.fool.com/investing/2021/01/21/3-top-stocks-for-retirees/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-21T06:15:00-05:00", "date_et": "2021-01-21"}
{"symbol": "LLY", "publishedDate": "2021-01-21 13:32:00", "publisher": "The Motley Fool", "title": "Eli Lilly's Antibody Reduces COVID-19 Risk by 80% in Nursing Homes", "image": "https://images.financialmodelingprep.com/news/eli-lillys-antibody-reduces-covid19-risk-by-80-in-20210121.jpg", "site": "fool.com", "text": "Results of a clinical trial suggest pre-emptive treatment with bamlanivimab can prevent COVID-19 from spreading through nursing homes.", "url": "https://www.fool.com/investing/2021/01/21/eli-lillys-antibody-reduces-covid-19-risk-by-80-in/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-21T13:32:00-05:00", "date_et": "2021-01-21"}
{"symbol": "LLY", "publishedDate": "2021-01-22 00:43:06", "publisher": "Seeking Alpha", "title": "Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73", "image": "https://images.financialmodelingprep.com/news/treating-the-causes-of-alzheimers-disease-the-case-for-20210122.jpg", "site": "seekingalpha.com", "text": "Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.", "url": "https://seekingalpha.com/article/4400329-treating-causes-of-alzheimers-disease-case-for-anavex-2minus-73", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-22T00:43:06-05:00", "date_et": "2021-01-22"}
{"symbol": "LLY", "publishedDate": "2021-01-22 08:55:00", "publisher": "PRNewsWire", "title": "Lilly Completes Acquisition of Prevail Therapeutics", "image": "https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-prevail-therapeutics-20210122.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's...", "url": "https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-prevail-therapeutics-301213219.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-22T08:55:00-05:00", "date_et": "2021-01-22"}
{"symbol": "LLY", "publishedDate": "2021-01-22 10:32:12", "publisher": "Zacks Investment Research", "title": "Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes", "image": "https://images.financialmodelingprep.com/news/lillys-lly-bamlanivimab-lowers-covid19-risk-in-nursing-homes-20210122.jpg", "site": "zacks.com", "text": "Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.", "url": "https://www.zacks.com/stock/news/1250485/lillys-lly-bamlanivimab-lowers-covid-19-risk-in-nursing-homes", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-22T10:32:12-05:00", "date_et": "2021-01-22"}
{"symbol": "LLY", "publishedDate": "2021-01-24 06:45:00", "publisher": "The Motley Fool", "title": "3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)", "image": "https://images.financialmodelingprep.com/news/3-top-healthcare-stocks-that-can-make-you-richer-20210124.jpg", "site": "fool.com", "text": "The future is bright for these three companies and investors who buy today could win big.", "url": "https://www.fool.com/investing/2021/01/24/3-top-healthcare-stocks-that-can-make-you-richer-i/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-24T06:45:00-05:00", "date_et": "2021-01-24"}
{"symbol": "LLY", "publishedDate": "2021-01-24 08:53:00", "publisher": "The Motley Fool", "title": "3 Blockbuster Drug Launches to Watch This Year", "image": "https://images.financialmodelingprep.com/news/3-blockbuster-drug-launches-to-watch-this-year-20210124.jpg", "site": "fool.com", "text": "These are the recently approved treatments biotech investors want to keep their eyes on in 2021.", "url": "https://www.fool.com/investing/2021/01/24/3-blockbuster-drug-launches-to-watch-this-year/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-24T08:53:00-05:00", "date_et": "2021-01-24"}
{"symbol": "LLY", "publishedDate": "2021-01-25 11:17:06", "publisher": "Zacks Investment Research", "title": "Will Eli Lilly (LLY) Beat Estimates This Earnings Season?", "image": "https://images.financialmodelingprep.com/news/will-eli-lilly-lly-beat-estimates-this-earnings-season-20210125.jpg", "site": "zacks.com", "text": "Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.", "url": "https://www.zacks.com/stock/news/1251358/will-eli-lilly-lly-beat-estimates-this-earnings-season", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-25T11:17:06-05:00", "date_et": "2021-01-25"}
{"symbol": "LLY", "publishedDate": "2021-01-26 06:45:00", "publisher": "PRNewsWire", "title": "New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent", "image": "https://images.financialmodelingprep.com/news/new-data-show-treatment-with-lillys-neutralizing-antibodies-bamlanivimab-20210126.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, \"events\") in high-risk patients recently diagnosed with COVID-19, meeting the primary...", "url": "https://www.prnewswire.com/news-releases/new-data-show-treatment-with-lillys-neutralizing-antibodies-bamlanivimab-ly-cov555-and-etesevimab-ly-cov016-together-reduced-risk-of-covid-19-hospitalizations-and-death--by-70-percent-301214598.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-26T06:45:00-05:00", "date_et": "2021-01-26"}
{"symbol": "LLY", "publishedDate": "2021-01-26 08:45:29", "publisher": "Market Watch", "title": "Lilly says late-stage study showed combo therapy can reduce deaths and hospitalizations in COVID-19 patients", "image": "https://images.financialmodelingprep.com/news/lilly-says-latestage-study-showed-combo-therapy-can-reduce-20210126.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. were up 0.3% in premarket trading on Tuesday after the drugmaker said combining two of its experimental COVID-19 antibody treatments can reduce hospitalizations and deaths in high-risk patients by up to 70%, based on findings from a Phase 3 clinical trial. The combination of bamlanivimab, which has received emergency use authorization in the U.S. as a standalone treatment for some COVID-19 patients, and the still-investigational etesevimab is being tested in about 1,000 patients.", "url": "https://www.marketwatch.com/story/lilly-says-late-stage-study-showed-combo-therapy-can-reduce-deaths-and-hospitalizations-in-covid-19-patients-2021-01-26", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-26T08:45:29-05:00", "date_et": "2021-01-26"}
{"symbol": "LLY", "publishedDate": "2021-01-26 10:10:00", "publisher": "Barron's", "title": "Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-regeneron-report-more-positive-data-on-20210126.jpg", "site": "barrons.com", "text": "Eli Lilly is back with another round of promising data on its Covid-19 antibody therapies.", "url": "https://www.barrons.com/articles/eli-lilly-regeneron-stock-data-covid-19-antibody-cocktails-51611673660", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-26T10:10:00-05:00", "date_et": "2021-01-26"}
{"symbol": "LLY", "publishedDate": "2021-01-27 06:45:00", "publisher": "PRNewsWire", "title": "Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19", "image": "https://images.financialmodelingprep.com/news/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-20210127.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk...", "url": "https://www.prnewswire.com/news-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial-evaluating-bamlanivimab-ly-cov555-with-vir-7831-gsk4182136-for-covid-19-301216017.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-27T06:45:00-05:00", "date_et": "2021-01-27"}
{"symbol": "LLY", "publishedDate": "2021-01-27 09:30:00", "publisher": "Forbes", "title": "Bristol Myers Squibb Stock Can Offer Better Returns Over Eli Lilly", "image": "https://images.financialmodelingprep.com/news/bristol-myers-squibb-stock-can-offer-better-returns-over-20210127.jpg", "site": "forbes.com", "text": "We think that Bristol Myers Squibb currently is a better pick compared to Eli Lilly & Company. BMY stock trades at about 3.7x trailing Revenues, compared to around 8.1x for LLY.", "url": "https://www.forbes.com/sites/greatspeculations/2021/01/27/bristol-myers-squibb-stock-can-offer-better-returns-over-eli-lilly/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-27T09:30:00-05:00", "date_et": "2021-01-27"}
{"symbol": "LLY", "publishedDate": "2021-01-27 11:17:10", "publisher": "Zacks Investment Research", "title": "Lilly's (LLY) Bamlanivimab Combo Lowers COVID-19 Hospitalization", "image": "https://images.financialmodelingprep.com/news/lillys-lly-bamlanivimab-combo-lowers-covid19-hospitalization-20210127.jpg", "site": "zacks.com", "text": "Eli Lilly's (LLY) combination of its COVID-19 antibodies bamlanivimab (LY-CoV555) plus etesevimab (LY-CoV016) reduces COVID-19-related hospitalizations and deaths by 70%.", "url": "https://www.zacks.com/stock/news/1252518/lillys-lly-bamlanivimab-combo-lowers-covid-19-hospitalization", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-27T11:17:10-05:00", "date_et": "2021-01-27"}
{"symbol": "LLY", "publishedDate": "2021-01-28 06:34:00", "publisher": "PRNewsWire", "title": "Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate", "image": "https://images.financialmodelingprep.com/news/lilly-and-asahi-kasei-pharma-announce-license-agreement-for-20210128.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS and TOKYO, Jan. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor...", "url": "https://www.prnewswire.com/news-releases/lilly-and-asahi-kasei-pharma-announce-license-agreement-for-chronic-pain-drug-candidate-301217103.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-28T06:34:00-05:00", "date_et": "2021-01-28"}
{"symbol": "LLY", "publishedDate": "2021-01-28 09:47:18", "publisher": "Zacks Investment Research", "title": "Is a Surprise Coming for Lilly (LLY) This Earnings Season?", "image": "https://images.financialmodelingprep.com/news/is-a-surprise-coming-for-lilly-lly-this-earnings-20210128.jpg", "site": "zacks.com", "text": "Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "url": "https://www.zacks.com/stock/news/1253139/is-a-surprise-coming-for-lilly-lly-this-earnings-season", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-28T09:47:18-05:00", "date_et": "2021-01-28"}
{"symbol": "LLY", "publishedDate": "2021-01-28 11:17:23", "publisher": "Zacks Investment Research", "title": "Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen", "image": "https://images.financialmodelingprep.com/news/lilly-lly-partners-virglaxo-for-covid19-combo-regimen-20210128.jpg", "site": "zacks.com", "text": "Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.", "url": "https://www.zacks.com/stock/news/1253318/lilly-lly-partners-vir-glaxo-for-covid-19-combo-regimen", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-28T11:17:23-05:00", "date_et": "2021-01-28"}
{"symbol": "LLY", "publishedDate": "2021-01-28 12:02:36", "publisher": "Zacks Investment Research", "title": "5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates", "image": "https://images.financialmodelingprep.com/news/5-big-pharmabiotech-stocks-set-to-trump-q4-earnings-20210128.jpg", "site": "zacks.com", "text": "Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.", "url": "https://www.zacks.com/stock/news/1253404/5-big-pharma-biotech-stocks-set-to-trump-q4-earnings-estimates", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-28T12:02:36-05:00", "date_et": "2021-01-28"}
{"symbol": "LLY", "publishedDate": "2021-01-29 06:20:00", "publisher": "PRNewsWire", "title": "Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results", "image": "https://images.financialmodelingprep.com/news/lilly-reports-strong-fourthquarter-and-fullyear-2020-financial-results-20210129.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Jan. 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2020. $ in millions, except per share data Fourth Quarter % Full Year % 2020 2019 Change 2020 2019 Change Revenue $ 7,440.0 $ 6,114.0 22%...", "url": "https://www.prnewswire.com/news-releases/lilly-reports-strong-fourth-quarter-and-full-year-2020-financial-results-301217838.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T06:20:00-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 06:37:19", "publisher": "Market Watch", "title": "Eli Lilly beats profit and sales forecasts, to deliver 500,000 more COVID-19 treatment doses by end of March", "image": "https://images.financialmodelingprep.com/news/eli-lilly-beats-profit-and-sales-forecasts-to-deliver-20210129.jpg", "site": "marketwatch.com", "text": "Eli Lilly & Co. reported Friday a big fourth-quarter profit beat and revenue that rose 22% to top forecasts, as it recognized $850 million in U.S. revenue for bamlanivimab, the drugmaker's treatment for mile to moderate COVID-19 that has been granted Emergency Use Authorization. The company said it has delivered 950,000 bamlanivimab doses to the U.S. government, and has agreed to deliver 500,000 more doses no later than March 31.", "url": "https://www.marketwatch.com/story/eli-lilly-beats-profit-and-sales-forecasts-to-deliver-500000-more-covid-19-treatment-doses-by-end-of-march-2021-01-29", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T06:37:19-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 06:39:00", "publisher": "Reuters", "title": "Eli Lilly profit rises 41.5% as COVID-19 drug lifts sales", "image": "https://images.financialmodelingprep.com/news/eli-lilly-profit-rises-415-as-covid19-drug-lifts-20210129.jpg", "site": "reuters.com", "text": "Eli Lilly and Co posted a 41.5% rise in fourth-quarter profit on Friday, helped by higher demand for its diabetes drugs and a successful launch of its COVID-19 antibody treatment.", "url": "https://www.reuters.com/article/us-lilly-results/eli-lilly-profit-rises-41-5-as-covid-19-drug-lifts-sales-idUSKBN29Y1CY", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T06:39:00-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 07:03:50", "publisher": "Benzinga", "title": "Recap: Eli Lilly Q4 Earnings", "image": "https://images.financialmodelingprep.com/news/recap-eli-lilly-q4-earnings-20210129.jpg", "site": "benzinga.com", "text": "Shares of Eli Lilly (NYSE:LLY) decreased 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 58.96% year over year to $2.75, which beat the estimate of $2.35.", "url": "https://www.benzinga.com/news/earnings/21/01/19390204/recap-eli-lilly-q4-earnings", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T07:03:50-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 10:32:53", "publisher": "Zacks Investment Research", "title": "Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales", "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-q4-earnings-top-covid19-antibody-boosts-20210129.jpg", "site": "zacks.com", "text": "Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.", "url": "https://www.zacks.com/stock/news/1254152/eli-lilly-lly-q4-earnings-top-covid-19-antibody-boosts-sales", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T10:32:53-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 11:16:00", "publisher": "Barron's", "title": "Lilly Reports Strong Sales, Boosted by Covid Antibodies", "image": "https://images.financialmodelingprep.com/news/lilly-reports-strong-sales-boosted-by-covid-antibodies-20210129.jpg", "site": "barrons.com", "text": "December's sales were as good as Wall Street expected, but profits came in about 9% better than the forecasts of analysts polled by FactSet.", "url": "https://www.barrons.com/articles/lilly-reports-strong-sales-boosted-by-covid-antibodies-51611936993", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T11:16:00-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 11:17:08", "publisher": "Zacks Investment Research", "title": "Personal Income Increased in December", "image": "https://images.financialmodelingprep.com/news/personal-income-increased-in-december-20210129.jpg", "site": "zacks.com", "text": "Personal Income Increased in December", "url": "https://www.zacks.com/stock/news/1254275/personal-income-increased-in-december", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T11:17:08-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 11:17:16", "publisher": "Zacks Investment Research", "title": "Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data", "image": "https://images.financialmodelingprep.com/news/economic-prints-q4-reports-up-for-lilly-cat-jj-20210129.jpg", "site": "zacks.com", "text": "With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.", "url": "https://www.zacks.com/stock/news/1254261/economic-prints-q4-reports-up-for-lilly-cat-jj-posts-phase-3-data", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T11:17:16-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 15:04:55", "publisher": "Schaeffers Research", "title": "Drug Stock Reverses from Record Highs Despite Blowout Earnings", "image": "https://images.financialmodelingprep.com/news/drug-stock-reverses-from-record-highs-despite-blowout-earnings-20210129.jpg", "site": "schaeffersresearch.com", "text": "The shares of Eli Lilly And Co (NYSE:LLY) are down 2.1% at $205.80 this afternoon -- likely due to some broad-market headwinds  -- despite earlier surging to an all-time high of $218.", "url": "https://www.schaeffersresearch.com/content/news/2021/01/29/drug-stock-reverses-from-record-highs-despite-blowout-earnings", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T15:04:55-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 15:31:07", "publisher": "Seeking Alpha", "title": "Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2020 Results - Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-ceo-dave-ricks-on-20210129.jpg", "site": "seekingalpha.com", "text": "Eli Lilly and Company (LLY) CEO Dave Ricks on Q4 2020 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4402125-eli-lilly-and-company-lly-ceo-dave-ricks-on-q4-2020-results-earnings-call-transcript", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T15:31:07-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-01-29 17:26:44", "publisher": "GuruFocus", "title": "Eli Lilly Tops Estimates With Government Purchases of Covid Treatment", "image": "https://images.financialmodelingprep.com/news/eli-lilly-tops-estimates-with-government-purchases-of-covid-20210129.jpg", "site": "gurufocus.com", "text": "Pharmaceutical manufacturer Eli Lilly and Co. (NYSE:LLY) has released strong earnings thanks to high demand for cancer and diabetes treatments alongside government purchases of its Covid-19 antibody treatment.", "url": "https://www.gurufocus.com/news/1344695/eli-lilly-tops-estimates-with-government-purchases-of-covid-treatment", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-01-29T17:26:44-05:00", "date_et": "2021-01-29"}
{"symbol": "LLY", "publishedDate": "2021-02-01 07:30:00", "publisher": "PRNewsWire", "title": "Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients", "image": "https://images.financialmodelingprep.com/news/lilly-partners-with-area-health-systems-to-help-enable-20210201.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Feb. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19...", "url": "https://www.prnewswire.com/news-releases/lilly-partners-with-area-health-systems-to-help-enable-access-to-important-antibody-infusion-therapies-for-covid-19-patients-301218598.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-01T07:30:00-05:00", "date_et": "2021-02-01"}
{"symbol": "LLY", "publishedDate": "2021-02-02 08:53:46", "publisher": "Deadline", "title": "Rebel Girls Taps Former WB, Disney Exec Soo Koo As Creative, Marketing Boss; Blavity's Lilly Workneh To Run Digital Content", "image": "https://images.financialmodelingprep.com/news/rebel-girls-taps-former-wb-disney-exec-soo-koo-20210202.jpg", "site": "deadline.com", "text": "EXCLUSIVE: Rebel Girls, the entertainment brand best known for the children's book series and podcast Good Night Stories for Rebel Girls has added former Warner Bros. and Disney exec Soo Koo and Lilly Workneh, former editor-in-chief of Blavity News, as, respectively, chief creative/marketing officer and head of digital content. The appointments follow a recent deal...", "url": "https://deadline.com/2021/02/rebel-girls-brand-names-former-wb-disney-exec-soo-koo-creative-lilly-workneh-digital-content-head-1234684988/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-02T08:53:46-05:00", "date_et": "2021-02-02"}
{"symbol": "LLY", "publishedDate": "2021-02-02 09:00:00", "publisher": "Seeking Alpha", "title": "Upcoming Ex-Dividend Dates: February 3-12, 2021", "image": "https://images.financialmodelingprep.com/news/upcoming-exdividend-dates-february-312-2021-20210202.jpg", "site": "seekingalpha.com", "text": "Upcoming Ex-Dividend Dates: February 3-12, 2021", "url": "https://seekingalpha.com/article/4402625-upcoming-ex-dividend-dates-february-3minus-12-2021", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-02T09:00:00-05:00", "date_et": "2021-02-02"}
{"symbol": "LLY", "publishedDate": "2021-02-02 13:53:38", "publisher": "Seeking Alpha", "title": "Bolt Biotherapeutics Aims For $150 Million U.S. IPO", "image": "https://images.financialmodelingprep.com/news/bolt-biotherapeutics-aims-for-150-million-us-ipo-20210202.jpg", "site": "seekingalpha.com", "text": "Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.", "url": "https://seekingalpha.com/article/4402758-bolt-biotherapeutics-aims-for-150-million-u-s-ipo", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-02T13:53:38-05:00", "date_et": "2021-02-02"}
{"symbol": "LLY", "publishedDate": "2021-02-03 17:16:00", "publisher": "PRNewsWire", "title": "Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day", "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-guggenheim-healthcare-talks-2021-oncology-20210203.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly Oncology, and Jacob Van Naarden, chief executive officer...", "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-guggenheim-healthcare-talks-2021-oncology-day-301221714.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-03T17:16:00-05:00", "date_et": "2021-02-03"}
{"symbol": "LLY", "publishedDate": "2021-02-04 06:42:00", "publisher": "The Motley Fool", "title": "Can This Maverick Biotech Become the Frontrunner in the Fight Against Alzheimer's?", "image": "https://images.financialmodelingprep.com/news/can-this-maverick-biotech-become-the-frontrunner-in-the-20210204.jpg", "site": "fool.com", "text": "Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.", "url": "https://www.fool.com/investing/2021/02/04/can-this-maverick-biotech-become-the-frontrunner-i/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-04T06:42:00-05:00", "date_et": "2021-02-04"}
{"symbol": "LLY", "publishedDate": "2021-02-05 13:38:16", "publisher": "Zacks Investment Research", "title": "Pharma ETFs in Focus Post Q4 Earnings", "image": "https://images.financialmodelingprep.com/news/pharma-etfs-in-focus-post-q4-earnings-20210205.jpg", "site": "zacks.com", "text": "Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.", "url": "https://www.zacks.com/stock/news/1258521/pharma-etfs-in-focus-post-q4-earnings", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-05T13:38:16-05:00", "date_et": "2021-02-05"}
{"symbol": "LLY", "publishedDate": "2021-02-07 07:00:00", "publisher": "Barron's", "title": "Big Pension Buys Up Alibaba, Lilly, and Cisco Stock. Here's What It Sold.", "image": "https://images.financialmodelingprep.com/news/big-pension-buys-up-alibaba-lilly-and-cisco-stock-20210207.jpg", "site": "barrons.com", "text": "State Teachers Retirement System of Ohio materially lifted investments in Alibaba, Eli Lilly, and Cisco Systems, and halved holdings in Salesforce.com in the fourth quarter.", "url": "https://www.barrons.com/articles/pension-buys-up-alibaba-stock-lilly-cisco-salesforce-51612454514", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-07T07:00:00-05:00", "date_et": "2021-02-07"}
{"symbol": "LLY", "publishedDate": "2021-02-07 15:38:12", "publisher": "Seeking Alpha", "title": "Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1", "image": "https://images.financialmodelingprep.com/news/week-in-review-junshi-signs-11-billion-deal-for-20210207.jpg", "site": "seekingalpha.com", "text": "Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1", "url": "https://seekingalpha.com/article/4404187-week-in-review-junshi-signs-1_1-billion-deal-for-u-s-canada-rights-to-pdminus-1", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-07T15:38:12-05:00", "date_et": "2021-02-07"}
{"symbol": "LLY", "publishedDate": "2021-02-09 07:18:48", "publisher": "Market Watch", "title": "Lilly promotes Anat Ashkenazi to CFO, says previous CFO had 'inappropriate' communication with employees", "image": "https://images.financialmodelingprep.com/news/lilly-promotes-anat-ashkenazi-to-cfo-says-previous-cfo-20210209.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. were down 0.3% in premarket trading on Tuesday after the drugmaker said chief financial officer Josh Smiley will resign after engaging in inappropriate personal communications with some employees. He had a personal relationship with an employee, which was found to be consensual.", "url": "https://www.marketwatch.com/story/lilly-promotes-anat-ashkenazi-to-cfo-says-previous-cfo-had-inappropriate-communication-with-employees-2021-02-09", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T07:18:48-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 07:21:00", "publisher": "Reuters", "title": "Eli Lilly says CFO to step down after 'inappropriate communication' with employees", "image": "https://images.financialmodelingprep.com/news/eli-lilly-says-cfo-to-step-down-after-inappropriate-20210209.jpg", "site": "reuters.com", "text": "Eli Lilly and Co said on Tuesday its chief financial officer Josh Smiley will step down after an independent investigation found inappropriate personal communication with certain Lilly employees.", "url": "https://www.reuters.com/article/us-lilly-cfo/eli-lilly-says-cfo-to-step-down-after-inappropriate-communication-with-employees-idUSKBN2A91KO", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T07:21:00-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 09:17:07", "publisher": "Proactive Investors", "title": "American Resources engages ex-Eli Lilly executive William Smith III to design and build its rare earth and critical mineral purification facilities", "image": "https://images.financialmodelingprep.com/news/american-resources-engages-exeli-lilly-executive-william-smith-iii-20210209.jpg", "site": "proactiveinvestors.com", "text": "American Resources Corporation (NASDAQ:AREC) announced Tuesday that it has engaged technology veteran William E. Smith III to lead the design, build and operation phase of its rare earth and critical mineral purification facilities.", "url": "https://www.proactiveinvestors.com//companies/news/940804/american-resources-engages-ex-eli-lilly-executive-william-smith-iii-to-design-and-build-its-rare-earth-and-critical-mineral-purification-facilities-940804.html?SNAPI", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T09:17:07-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 09:37:37", "publisher": "CNN", "title": "Eli Lilly CFO resigns after 'inappropriate' communications with employees", "image": "https://images.financialmodelingprep.com/news/eli-lilly-cfo-resigns-after-inappropriate-communications-with-employees-20210209.jpg", "site": "cnn.com", "text": "Eli Lilly announced that Josh Smiley, its chief financial officer and senior vice president, has resigned after an investigation revealed \"inappropriate personal communications\" with employees.", "url": "https://www.cnn.com/2021/02/09/business/eli-lilly-cfo-resigns/index.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T09:37:37-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 10:04:57", "publisher": "24/7 Wall Street", "title": "Eli Lilly Dumps CFO After Inappropriate Communication Allegations Arise", "image": "https://images.financialmodelingprep.com/news/eli-lilly-dumps-cfo-after-inappropriate-communication-allegations-arise-20210209.jpg", "site": "247wallst.com", "text": "Eli Lilly and Co. (NYSE: LLY) is shuffling the executive deck on Tuesday after allegations about inappropriate communication arose against Chief Financial Officer Josh Smiley.", "url": "https://247wallst.com/healthcare-business/2021/02/09/eli-lilly-dumps-cfo-after-inappropriate-communication-allegations-arise/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T10:04:57-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 12:53:52", "publisher": "Zacks Investment Research", "title": "ABBV or LLY: Which Is the Better Value Stock Right Now?", "image": "https://images.financialmodelingprep.com/news/abbv-or-lly-which-is-the-better-value-stock-20210209.jpg", "site": "zacks.com", "text": "ABBV vs. LLY: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/1260012/abbv-or-lly-which-is-the-better-value-stock-right-now", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T12:53:52-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 17:24:19", "publisher": "GuruFocus", "title": "Primecap Management's Top Trades of the 4th Quarter", "image": "https://images.financialmodelingprep.com/news/primecap-managements-top-trades-of-the-4th-quarter-20210209.jpg", "site": "gurufocus.com", "text": "PRIMECAP Management ( Current Portfolio ) has revealed its portfolio for the fourth quarter. Major trades include a new buy in Morgan Stanley (NYSE:MS) and reductions in Qualcomm Inc. (NASDAQ:QCOM), Adobe Inc. (NASDAQ:ADBE), Microsoft Corp. (NASDAQ:MSFT) and Alphabet Inc. (NASDAQ:GOOG).", "url": "https://www.gurufocus.com/news/1354803/primecap-managements-top-trades-of-the-4th-quarter", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T17:24:19-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-09 19:29:00", "publisher": "PRNewsWire", "title": "Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19", "image": "https://images.financialmodelingprep.com/news/lillys-bamlanivimab-lycov555-administered-with-etesevimab-lycov016-receives-fda-20210209.jpg", "site": "prnewswire.com", "text": "INDIANAPOLIS, Feb. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for investigational bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced today. This therapy...", "url": "https://www.prnewswire.com/news-releases/lillys-bamlanivimab-ly-cov555-administered-with-etesevimab-ly-cov016-receives-fda-emergency-use-authorization-for-covid-19-301225460.html", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-09T19:29:00-05:00", "date_et": "2021-02-09"}
{"symbol": "LLY", "publishedDate": "2021-02-10 04:13:58", "publisher": "Benzinga", "title": "Eli Lilly Antibody Drug Combo For COVID-19 Gets FDA Emergency Approval", "image": "https://images.financialmodelingprep.com/news/eli-lilly-antibody-drug-combo-for-covid19-gets-fda-20210210.jpg", "site": "benzinga.com", "text": "Eli Lilly and Co (NYSE: LLY)'s antibody treatments have received an emergency use authorization from the United States Food and Drug Administration. What Happened: The federal regulator issued the EUA for the two drugs, bamlanivimab and etesevimab, to be administered together for the treatment of mild to moderate COVID-19 in both adults and children above 12 years of age.", "url": "https://www.benzinga.com/general/biotech/21/02/19579646/eli-lilly-antibody-drug-combo-for-covid-19-gets-fda-emergency-approval", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-10T04:13:58-05:00", "date_et": "2021-02-10"}
{"symbol": "LLY", "publishedDate": "2021-02-10 08:05:13", "publisher": "Market Watch", "title": "FDA grants authorization to Lilly's COVID-19 antibody treatment", "image": "https://images.financialmodelingprep.com/news/fda-grants-authorization-to-lillys-covid19-antibody-treatment-20210210.jpg", "site": "marketwatch.com", "text": "Shares of Eli Lilly & Co. were up 1.1% in premarket trading on Wednesday, the day after the Food and Drug Administration granted emergency authorization to the company's COVID-19 antibody cocktail. The infusion pairs two monoclonal antibodies, bamlanivimab and etesevimab, as a treatment for anyone older than 12 years old who has mild to moderate COVID-19 symptoms and is at risk for severe disease.", "url": "https://www.marketwatch.com/story/fda-grants-authorization-to-lillys-covid-19-antibody-treatment-2021-02-10", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-10T08:05:13-05:00", "date_et": "2021-02-10"}
{"symbol": "LLY", "publishedDate": "2021-02-10 11:41:22", "publisher": "Zacks Investment Research", "title": "Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod", "image": "https://images.financialmodelingprep.com/news/lilly-lly-covid19-antibody-combo-gets-fdas-emergency-nod-20210210.jpg", "site": "zacks.com", "text": "FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.", "url": "https://www.zacks.com/stock/news/1260769/lilly-lly-covid-19-antibody-combo-gets-fdas-emergency-nod", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-10T11:41:22-05:00", "date_et": "2021-02-10"}
{"symbol": "LLY", "publishedDate": "2021-02-11 06:25:00", "publisher": "The Motley Fool", "title": "How Risky Are These Heavily Shorted COVID Stocks?", "image": "https://images.financialmodelingprep.com/news/how-risky-are-these-heavily-shorted-covid-stocks-20210211.jpg", "site": "fool.com", "text": "These biotech companies may be among the winners of the coronavirus treatment race -- if all goes well in clinical trials.", "url": "https://www.fool.com/investing/2021/02/11/how-risky-are-these-heavily-shorted-covid-stocks/", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-11T06:25:00-05:00", "date_et": "2021-02-11"}
{"symbol": "LLY", "publishedDate": "2021-02-12 14:33:04", "publisher": "GuruFocus", "title": "Eli Lilly Keeps Piling Up Share Price Gains", "image": "https://images.financialmodelingprep.com/news/eli-lilly-keeps-piling-up-share-price-gains-20210212.jpg", "site": "gurufocus.com", "text": "Eli Lilly and Co.'s (NYSE:LLY) 28% increase in share price in 2020 was the highest among members of big [harma. According to an Evaluate Pharma report, the gain pushed the company's market value to more than $161 billion.", "url": "https://www.gurufocus.com/news/1358266/eli-lilly-keeps-piling-up-share-price-gains-", "ticker": "LLY", "event_date": "2021-01-29", "window_start": "2021-01-15", "window_end": "2021-02-12", "publishedDateET": "2021-02-12T14:33:04-05:00", "date_et": "2021-02-12"}
